Boehringer Ingelheim Pharmaceuticals manufactures Jardiance ... dose to 25 milligrams if you need additional control of your blood sugar. As it says in the commercial, you take Jardiance "at each ...

The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...

Boehringer Ingelheim says it is on track to launch ... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.

Privately-held German drugmaker Boehringer Ingelheim and researchers from the Stanley Center for Psychiatric Research at the ...

Boehringer Ingelheim has halted development of an obesity drug from Gubra that it originally pledged to advance back in 2017, ...

Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the oncology-focused platform company’s decision to file for bankruptcy. Notable's ...

Substantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients with proof-of-concept data expected ...

Boehringer Ingelheim has taken an option on a family ... an option fee of €60 million and development, regulatory, and commercial milestone payments that could reach €670 million plus royalties.

The state-of-the-art research and development center in Georgia will help improve the health and wellbeing of animals ...

The National Turkey Federation supports import permit to improve treatment of the contagious respiratory disease.

Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity.

No. 49 / 2024Zealand Pharma Announces Financial Results for the First Nine Months of 2024Continued strong progress across ...